The effect of reducing heart rate on central aortic blood pressure: a comparative study of ivabradine and atenolol on haemodynamic parameters at rest

2013 ◽  
Author(s):  
Ian Wilkinson
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Comparative Study ◽  
Haemodynamic Parameters ◽  
Aortic Blood ◽  
Aortic Blood Pressure ◽  
Central Aortic Blood Pressure

Abstract 16763: Unchanged Central Aortic Blood Pressure and Increased Myocardial Perfusion in Patients With Stable Coronary Artery Disease Receiving Ivabradine

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Bernard I. Levy ◽  
Jean-Guillaume Dillinger ◽  
Patrick Henry ◽  
Damien Logeart ◽  
Stephane Manzo Silberman ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Myocardial Perfusion ◽  
Beta Blocker ◽  
Central Blood Pressure ◽  
Pronounced Increase ◽  
Aortic Blood ◽  
Perfusion Time ◽  
Aortic Blood Pressure ◽  
Central Aortic Blood Pressure

Background: Treatment of hypertensive patients with beta-blockers reduces heart rate (HR) and increases central blood pressure, implying that the decrease in HR could explain reported increases in cardiovascular risk with beta-blocker. This analysis from a randomized, double-blind study explores whether HR reduction with the I f inhibitor ivabradine had an impact on central blood pressure and coronary perfusion. Methods and results: We included 12 normotensive patients with stable CAD, HR ≥70 bpm (sinus rhythm), and stable background beta-blocker therapy. Patients received ivabradine 7.5 mg bid or matched placebo for two 3-week periods with a crossover design and evaluation by aplanation tonometry. Treatment with ivabradine was associated with a significant reduction in resting HR after 3 weeks versus no change with placebo (-15.8±7.7 versus +0.3±5.8 bpm, p=0.0010). There was no relevant between-group difference in change in central aortic SBP (-4.0±9.6 versus +2.4±12.0 mm Hg, p=0.13) or augmentation index (-0.8±10.0% versus +0.3±7.6%, p=0.87). Treatment with ivabradine was associated with prolongation of diastolic perfusion time by 41% from baseline to 3 weeks (+215.6±105.3 versus -3.0±55.8 ms with placebo, p=0.0005) (Figure) and with a pronounced increase in an index of myocardial viability (Buckberg index, +39.3±27.6% versus -2.5±13.5% with placebo, p=0.0015). There were no safety issues during the study. Conclusion: Heart rate reduction with ivabradine does not modify central aortic blood pressure and is associated with a marked prolongation of diastolic perfusion time and an improvement in myocardial perfusion.

The differential impact of aerobic and isometric handgrip exercise on blood pressure variability and central aortic blood pressure

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Maximilian Seidel ◽  
Nikolaos Pagonas ◽  
Felix S. Seibert ◽  
Frederic Bauer ◽  
Benjamin Rohn ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Variability ◽  
Handgrip Exercise ◽  
Isometric Handgrip ◽  
Differential Impact ◽  
Aortic Blood ◽  
Isometric Handgrip Exercise ◽  
Aortic Blood Pressure ◽  
Central Aortic Blood Pressure
Sign in / Sign up

Export Citation Format

Share Document